sabarubicin has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, K | 1 |
| Aamdal, S; Bortini, S; Bos, AM; Capriati, A; Crea, AE; de Vries, EG; Dombernovsky, P; Hanauske, AR; Roelvink, MW; Schrijvers, D; Uges, DR; Vermorken, JB; Wanders, J | 1 |
| Bortini, S; Bos, AM; de Vries, EG; Dyck, J; Fumoleau, P; Roelvink, M; Schrijvers, D; Vermorken, JB; Wanders, J | 1 |
1 review(s) available for sabarubicin and Neoplasms
| Article | Year |
|---|---|
MEN-10755. Menarini.
Topics: Animals; Clinical Trials as Topic; Disaccharides; DNA Topoisomerases, Type II; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Technology, Pharmaceutical; Topoisomerase II Inhibitors | 2003 |
2 trial(s) available for sabarubicin and Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Child; Disaccharides; Doxorubicin; Female; Humans; Kidney; Male; Middle Aged; Neoplasms | 2001 |
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Disaccharides; Doxorubicin; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Safety | 2002 |